AVEO Pharmaceuticals (AVEO) Stock Adds 18.7%: How Does it Score?

Thursday, August 1, 2019 1:16 PM | InvestorsObserver Analysts

AVEO Pharmaceuticals (AVEO) stock is up 18.7% Thursday. AVEO stock is lower by -65.26% over the last 12 months, and the average rating from Wall Street analysts is a Moderate Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives AVEO stock a score of 41 out of a possible 100.

That score is primarily influenced by a long-term technical score of 16. AVEO's score also includes a short-term technical score of 38. The fundamental score for AVEO is 67. In addition to the average rating from Wall Street analysts, AVEO stock has a mean target price of $1.75. This means analysts expect the stock to add 136.49% over the next 12 months.

Click Here to get the full Stock Score Report on AVEO Pharmaceuticals, Inc. (AVEO).

What's Happening with AVEO Stock Today

AVEO Pharmaceuticals, Inc. (AVEO) stock has gained 18.7% while the S&P 500 is up 1% as of 12:59 PM on Thursday, Aug 1. AVEO is up $0.12 from the previous closing price of $0.62 on volume of 13,337,640 shares. Over the past year the S&P 500 is higher by 6.89% while AVEO is lower by -65.26%. AVEO lost -$0.04 per share in the over the last 12 months.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Should You Buy Dare Bioscience (DARE) Stock Monday?

Should You Buy Clovis Oncology (CLVS) Stock Monday?

Analysts Expect Protalix Biotherapeutics (PLX) Stock to Rises 540%; Rated Strong Buy

Hepion Pharmaceuticals (HEPA) Stock Adds 97.6%%: How Does it Score?

Ra Pharmaceuticals (RARX) Stock Rises 101%; Rated Strong Buy

Analysts Expect NGM Biopharmaceuticals (NGM) Stock to Rise 132.5%; Rated Strong Buy

Related Companies